Related Experiment Video
Updated: Jun 26, 2026
10:28
Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
Published on: March 15, 2022
Interindividual variability in the response to oral antiplatelet drugs: a position paper of the Working Group on
Wiktor Kuliczkowski1, Adam Witkowski, Lech Polonski
13rd Department of Cardiology, Silesian Center for Heart Diseases, Zabrze, Poland.
European Heart Journal
|January 29, 2009
Summary
Residual platelet activity despite oral antiplatelet drugs like aspirin and clopidogrel may explain ongoing cardiovascular events. Further research is needed to clarify this "resistance" and improve patient outcomes.
Area of Science:
- Cardiovascular Medicine
- Pharmacology
- Thrombosis Research
Background:
- Oral antiplatelet drugs, including aspirin and clopidogrel, are vital for managing atherothrombotic diseases.
- Despite established efficacy, cardiovascular events persist in patients on chronic antiplatelet therapy.
Purpose of the Study:
- To summarize current knowledge on residual platelet activity and its link to clinical outcomes.
- To address controversies and guide future research in oral antiplatelet drug resistance.
Main Methods:
- Review of existing literature on laboratory tests measuring platelet activity.
- Expert consensus and position paper development by cardiology and thrombosis working groups.
Main Results:
- Evidence suggests a correlation between high residual platelet activity and adverse clinical events.
- The concept of 'resistance' to oral antiplatelet drugs is proposed as a potential cause for treatment failure.
Conclusions:
- Residual platelet activity is a significant concern in cardiovascular atherothrombotic diseases.
- Further research is essential to establish reliable diagnostic tools and therapeutic strategies for managing antiplatelet drug resistance.
Related Concept Videos
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:27Coronary Artery Disease V: Interprofessional Care
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
01:16Drug toxicity: Idiosyncratic Reactions
Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...
01:24Dosage Regimen: Individualization
Individualization in dosing regimens is the customization of medication doses for individual patients. Its necessity arises from the goal of maximizing therapeutic benefits while minimizing risks. This approach is pivotal because human responses to drugs can vary widely; what is effective for one person may be inadequate or excessive for another. Interpatient (intersubject) variability refers to differences in drug responses between individuals, while intrapatient (intrasubject) variability...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:27Peripheral Artery Disease III: Interprofessional Care
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...